All In Biotech

Drug Trial Radar · NCT04245397

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

151

Planned (sponsor's estimate)

Start

Jun 30, 2020

Primary completion

Mar 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Syntrix Biosystems, Inc.Industry
Sponsor type
Industry
Collaborators
H. Lee Moffitt Cancer Center and Research Institute; National Heart, Lung, and Blood Institute (NHLBI); AdventHealth; Emory University; University of Miami; Mayo Clinic; Montefiore Medical Center; National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
First posted
Jan 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

Conditions

  • Myelodysplastic Syndromes

Interventions

  • SX-682Drug

    SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

  • DecitabineDrug

    Decitabine is a hypomethylating agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SX-682 Maximum Tolerated Dose (MTD)Time frame: Up to 28 days in the 28 day Cycle 1.
  2. SX-682 Dose Limiting Toxicities (DLT)Time frame: Up to 28 days in the 28 day Cycle 1.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • AdventHealth Medical Group & Bone Marrow Transplant at Orlando

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.